Press Release

PhRMA Statement on the Comparative Effectiveness Council

PhRMA May 1, 2013

Washington, D.C. (March 19, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today regarding the Federal Coordinating Council on Comparative Effectiveness Research:

“The economic stimulus law made an important footprint in the health care debate by providing significant funds for government-sponsored comparative effectiveness research (CER). PhRMA has long supported well-designed CER because when used correctly, it can serve as a tool to help improve patient outcomes and medical decision-making.

“To help ensure that CER is used to promote patient health and improve the quality of health care in the U.S., it is critical that the new Federal Coordinating Council listen carefully to input from all stakeholders throughout the process, particularly physician and patient input because, ultimately, they will be ones most impacted by the Council’s recommendations.

“As the Administration continues to implement this initiative, we expect it will be done with transparency, openness, accountability and public input in how research priorities are set and how studies are ultimately communicated and conducted.

"We look forward to working with members of Congress and the Administration as a long-term framework for comparative clinical effectiveness research is established.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on the danger of imported drugs, visit: